JAHA:心脏无创诊断试在门诊心绞痛患者的应用

2020-07-02 MedSci原创 MedSci原创

尽管在美国,每年对稳定的冠状动脉疾病进行的心脏无创诊断试验(NIT)超过400万次,目前尚不清楚与无检测相比,它们是否与预后的改善有关。本研究的目的旨在评估NIT是否与预后的改善相关。

尽管在美国,每年对稳定的冠状动脉疾病进行的心脏无创诊断试验(NIT)超过400万次,目前尚不清楚与无检测相比,它们是否与预后的改善有关。本研究的目的旨在评估NIT是否与预后的改善相关。

本研究纳入分析了约150万接受了胸痛检查的患者,并分成NIT组和对照组。与对照组相比,接受非侵入性试验的患者的不良事件发生率约降低25%(危险比[HR],0.77;95%CI,0.75-0.79)。该复合终点的所有3个成分的试验益处是一致的:不稳定心绞痛(NIT组与未试验组相比,HR为0.87;95%CI为0.82-0.93),心肌梗死(NIT组为0.83;95%CI为0.79-0.86)和血管死亡率(HR,0.68;95%CI,NIT组为0.65-0.72,与未测试组相比)。

研究结果显示,对于门诊稳定性心绞痛接受检查的患者来说,进行的心脏无创诊断试验的患者的不良事件发生率要更低。

原始出处:

Idan R et al.Clinical Effectiveness of Cardiac Noninvasive Diagnostic Testing in Outpatients Evaluated for Stable Coronary Artery Disease.JAHA.2020 July.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080900, encodeId=89b6208090046, content=<a href='/topic/show?id=d440589123f' target=_blank style='color:#2F92EE;'>#无创诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58912, encryptionId=d440589123f, topicName=无创诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Thu Jan 21 19:44:31 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805061, encodeId=4c968050618d, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17cd33819, createdName=mqh613mqh, createdTime=Wed Jul 29 14:38:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268284, encodeId=d4f7126828493, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 04 02:44:31 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080900, encodeId=89b6208090046, content=<a href='/topic/show?id=d440589123f' target=_blank style='color:#2F92EE;'>#无创诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58912, encryptionId=d440589123f, topicName=无创诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Thu Jan 21 19:44:31 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805061, encodeId=4c968050618d, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17cd33819, createdName=mqh613mqh, createdTime=Wed Jul 29 14:38:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268284, encodeId=d4f7126828493, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 04 02:44:31 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
    2020-07-29 mqh613mqh

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2080900, encodeId=89b6208090046, content=<a href='/topic/show?id=d440589123f' target=_blank style='color:#2F92EE;'>#无创诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58912, encryptionId=d440589123f, topicName=无创诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Thu Jan 21 19:44:31 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805061, encodeId=4c968050618d, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17cd33819, createdName=mqh613mqh, createdTime=Wed Jul 29 14:38:26 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268284, encodeId=d4f7126828493, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 04 02:44:31 CST 2020, time=2020-07-04, status=1, ipAttribution=)]
    2020-07-04 zhaohui6731

相关资讯

JACC:他汀可能降低健康老年人残疾和心血管疾病风险

对于年龄≥70岁的健康受试者,他汀类药物的益处和危害存在临床不确定性。这项研究的目的是在健康老年人中研究他汀类药物、无痴呆症和无残疾生存率以及心血管疾病(CVD)之间的关系。

Eur Heart J:Alirocumab 对高龄冠心病患者预后的影响研究

降低低密度脂蛋白胆固醇(LDL-C)可降低心血管风险,而与年龄无关,但对老年患者来说,这一证据并不那么有力。

Eur Heart J:他汀类药物可明显增加血浆脂蛋白a的水平

脂蛋白(a)[LP(a)]在20%-30%的人群中都存在升高,本研究的目的旨在评估他汀类药物治疗对脂蛋白(a)水平的影响。

PeerJ:颈动脉内-中膜厚度与突发感音神经性耳聋相关性研究

心血管因素与突发感音神经性耳聋(SSNHL)的病理生理特性和风险存在相关性。然而,关于颈动脉内-中膜厚度(IMT)与SSNHL风险和各自的治疗结果之间的关系仍旧了解很少。

Eur Heart J:血浆甘油三酯升高可增加主动脉瓣狭窄发生风险

本研究的目的旨在验证血浆甘油三酯和残余胆固醇水平的升高与主动脉瓣狭窄风险的增加有关。

JACC:压力反射疗法可明显改善心衰患者生活质量

本研究旨在证明压力反射激活疗法(BAT)对射血分数降低的心力衰竭患者(HFrEF)的安全性和有效性。